IgA肾病治疗研究进展

Research progress in the treatment of IgA nephropathy

IgA肾病(IgAN)是成人常见的原发性肾小球疾病,约30%~40%的患者可能在20 a内进展为终末期肾病;由于对IgAN发病机制的了解不充分,目前其治疗仍以支持治疗为主。鉴于糖皮质激素、免疫抑制剂等传统药物疗效有限且存在一定不良反应,靶向治疗及分子生物疗法等已成为研究热点。本文就近年来关于IgAN的支持治疗、糖皮质激素和免疫抑制剂等传统药物治疗以及靶向治疗和分子生物治疗等新兴疗法的研究进展进行综述,以期为探索IgAN的管理和治疗提供新的思路与方向。

IgA nephropathy(IgAN)is a common primary glomerular disease in adults,and about 30%-40%of patients may progress to end-stage renal disease within 20 years.Due to insufficient understanding of its pathogenesis,supportive care is still mainly treatment for IgAN at present.Given the limited efficacy and side effects of traditional medicines,such as glucocorticoids and immunosuppressant,targeted therapy and molecular biological therapy have becoming research hotspot.This article reviews the progress in supportive care,traditional medicines such as glucocorticoids and immunosuppressant,and new treatment strategy such as targeted therapy and molecular biological therapy of IgAN in recent years,so as to provide strategies and directions for exploring the management and treatment of IgAN.